Oric Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

ORIC Pharmaceuticals

07/11/2022 22:05

* Oric Pharmaceuticals Inc  ORIC.OQ  reported a quarterly
adjusted
loss of 63 cents​​ per share for the quarter ended in September.
The mean expectation of seven analysts for the quarter was for a
loss of 55 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Oric Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 63 cents​.
    * The mean earnings estimate of analysts had risen by
about 9.9%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Oric Pharmaceuticals Inc shares had fallen by 23.1% this
quarter and lost 83.3% so far this year.
    * The company reported a quarterly loss of $24.83 million.
    * Wall Street's median 12-month price target for Oric
Pharmaceuticals Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
7 at 10:05 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.55          -0.63          Missed
 Jun. 30 2022      -0.60          -0.51          Beat
 Mar. 31 2022      -0.57          -0.59          Missed
 Dec. 31 2021      -0.57          -0.58          Missed